Prolonged intermittent renal replacement therapy (PIRRT) is a recently defined acute modality for critically ill patients, and in theory combines the superior detoxification and haemodynamic stability of continuous renal replacement therapy (CRRT) with the operational convenience and low cost of intermittent haemodialysis (iHD). We performed a retrospective cohort study for all critically ill adults treated with renal replacement therapy at our centre in Auckland, New Zealand from 1 January 2002 to 31 December 2008. The exposure of interest was modality (PIRRT, CRRT, iHD). Primary and secondary outcomes were patient mortality determined at hospital discharge and 90 days post renal replacement therapy inception, respectively. Co-variates included co-morbidity and baseline illness severity measured by Acute Physiology and Chronic Health Evaluation IV and Sepsis-Related Organ Failure Assessment (SOFA) and time-varying illness severity measured by daily SOFA scores. We used Marginal Structural Modelling to estimate mortality risk adjusting for both time-varying illness severity and modality exposure. A total of 146 patients with 633 treatment-days had sufficient data for modelling. With PIRRT as the reference, the adjusted hazard ratios for patient hospital mortality were 1.31 (0.60 to 2.90) for CRRT and 1.22 (0.21 to 2.29) for iHD. Corresponding estimates for mortality at 90 days were 0.96 (0.39 to 2.36) and 2.22 (0.49 to 10.11), respectively, reflecting the poorer longer-term prognosis of patients still on iHD at hospital discharge with delayed or non-recovery of acute kidney injury. Our study supports the recent increased use of PIRRT, which within limits can be regarded as safe and effective.
population may be improving slowly although it is still high at up to 50% [1] [2] [3] . The most common modalities of acute renal replacement therapy are continuous renal replacement therapy (CRRT) and intermittent haemodialysis (iHD) 4, 5 . Clinical trials have failed to show superiority of one over the other in terms of mortality risk for unselected critically ill patients [6] [7] [8] , although cumulative clinical experience suggests that CRRT is better tolerated by haemodynamically unstable patients.
Prolonged intermittent renal replacement therapy (PIRRT) is a more recently defined acute modality that is also known as extended (daily) dialysis or sustained low-efficiency (daily) dialysis/diafiltration [9] [10] [11] [12] [13] [14] [15] [16] . PIRRT involves the application of conventional Anaesthesia and Intensive Care, Vol. 40, No. 2, March 2012 iHD machinery with reduced blood and dialysate flow rates for prolonged periods. PIRRT combines the superior detoxification and haemodynamic stability of CRRT with the operational convenience and low cost of iHD. However, there are fewer outcomes studies with PIRRT than there are with are CRRT or iHD. The cohort studies that do exist are often confounded by selection bias, time-varying modality exposure and time-varying illness severity, factors that can all lead to potentially incorrect estimates of mortality risk 12, 17, 18 . A suitably powered randomised clinical trial would provide definitive outcome data, but is unlikely given the other more pressing priorities for research within critical care nephrology.
A number of advanced statistical techniques have recently been described which may improve the validity of cohort studies in this area. Using one such technique, we studied critically ill patients treated with renal replacement therapy in our centre and compared mortality risk by modality. We used the Marginal Structural Modelling (MSM) approach of Robins to adjust for multiple confounders including time-varying modality exposure, and also time-varying illness severity that is both affected by previous modality exposure while also affecting subsequent modality choice 19 . We present partially and fully adjusted estimates of the mortality risks associated with different acute modalities in our centre, including PIRRT.
METHODS

Study design
We performed an inception cohort study, using an as-treated framework ("did the modality that the patient actually received affect outcomes?"), as opposed to an intention-to-treat framework ("did the initial modality that the patient receive affect outcomes, irrespective of subsequent changes that occurred along the way?") 20 . Data were sourced from patients' hospital and primary care clinical records. We performed analyses of repeated measures within patients over time.
Setting and participants
We created an inception cohort of all adult renal replacement therapy patients (>16 years) admitted to the intensive care unit (ICU) of Middlemore Hospital, Counties Manukau District Health Board, Auckland, New Zealand from January 2002 to December 2008. Middlemore Hospital is a 900-bed tertiary referral centre for plastic surgery, burns, orthopaedics and a range of medical sub-specialities. Any patient requiring neurosurgical or cardio-thoracic surgical intervention is referred on; all other patients remain at Middlemore Hospital. Currently, the ICU in the hospital is a 12 fundedbed level 3 facility 21 . Patients were followed until death, hospital discharge or 90 days post renal replacement therapy inception, whichever occurred first. Censoring was at the time of loss to follow-up. We included patients with AKI or acute-on-chronic kidney disease as defined by the 'Failure' stage of the RIFLE (Risk, Injury, Failure, Loss, End-stage kidney disease) criteria 22 , and excluded those with end-stage kidney failure on maintenance dialysis and those with normal renal function requiring renal replacement therapy for treatment of poisoning. Of note, we only analysed a patient's first ICU admission if they were re-admitted to the ICU during the same hospitalisation. This is a standard approach and avoids counting more than one outcome for the same patient.
Primary exposure and outcome variables
The primary exposure was time-varying acute modality: PIRRT, CRRT or iHD 9, 23 . All treatments in our centre irrespective of modality were delivered via standard veno-venous access, with unfractionated heparin for anticoagulation, using synthetic haemofilters and haemodialysers (polysulfone, polyamide, AN-69). PIRRT was performed using Fresenius 4008S ARrT-Plus or 5008 machines (Fresenius Medical Care (New Zealand) Pty Ltd, Auckland, New Zealand), using blood flow rate (QB) of 200 to 300 ml/minute, with counter-current bicarbonate-based dialysate with flow rate (QD) of 200 ml/minute, and haemofiltration between 25 to 100 ml/minute in prefilter mode. Treatment duration was prescribed at between 8 to 10 hours on a daily or alternate day basis as clinically indicated for solute or fluid control. On-line replacement fluid was produced using portable reverse osmosis water and at two in-line dialysate filters, a technique that has been validated previously. Ultrapure water quality was ensured by regular endotoxin and microbiological testing according to standard guidelines ( CRRT was performed using Baxter Aquarius (Baxter Healthcare New Zealand, Auckland, New Zealand) or Prisma machines (Gambro New Zealand Pty Ltd, Botany, New Zealand) by haemo-filtration or haemodiafiltraion using bicarbonatebased replacement fluid (Hemosol B0) in postdilution mode. (QB ranged from 150 to 200 ml/ minute, with pump-controlled ultrafiltration or dialysis at 1500 to 2500 ml/hour).
iHD was performed using Gambro AK200S machines with QB 250 to 300 ml/minute, and counter-current bicarbonate-based dialysate with QD 500 to 700 ml/minute. Treatment duration was prescribed at between four and six hours on a daily or alternate day basis as clinically indicated for solute or fluid control. Dialysate was produced using portable reverse osmosis water and one in-line dialysate filter. Ultrapure water quality was ensured by regular endotoxin and microbiological testing according to standard guidelines. The dialysate used constituent concentrations (mmol/l) as clinically appropriate: [Na + ] 140-145, [K + ] 2-3, [Ca 2+ ] 1.25 and [HCO 3 -] 35-40. The primary outcome was patient death determined at hospital discharge. The secondary outcome was patient death determined at 90 days post renal replacement therapy inception.
Data measurement and quantitative variables
We adjusted for known risk factors as recorded in patients' clinical records: baseline illness severity and co-morbidity as measured by the Acute Physiological and Chronic Health Evaluation (APACHE) IV score and predicted risk of death 24 , time-varying illness severity as measured by daily Sepsis-Related Organ Failure Assessment (SOFA) scores, time from ICU admission to renal replacement therapy inception 25 , and year of admission to account for any secular variation.
Statistical methods
Data for analyses consisted of T daily waves for each of n patients for a total of n*T patient-days. Each wave contained the primary exposure and outcome and also potential confounders for that day. Variables were modelled as baseline or time-varying as appropriate by carrying forward either patients' first or most recent observations respectively.
We used the MSM technique of Robins to adjust for time-varying modality exposure and illness severity 19, [26] [27] [28] [29] . MSMs relate potential outcomes to exposure history, using weights that redistribute the population so that the primary exposure is unconfounded. In our study the main source of confounding is illness severity. CRRT is used rather than PIRRT and IHD for patients with higher degrees of illness severity and adjustment is necessary to avoid selection bias. However, illness severity is also an intermediary variable on the causal pathway to death; modality exposure may affect the development of new haemodynamic instability, which is an independent prognostic factor for death. Controlling for illness severity alone would result in biased estimates of the effect of modality, as any effect of modality exposure acting via illness severity would be lost 19, 30, 31 . In our analyses, weights remove associations between dialysis modality and prior illness severity, and also between prior modality exposure and the development of worsening illness severity.
Using this technique, we calculated the hazard ratio for mortality for each of the three possible acute modalities. The estimated hazard functions can be interpreted as individuals' mortality outcomes had they (possibly contrary to fact) been continuously treated with the given modality. Results from such 'counterfactual' analyses more closely approximate those of clinical trials than standard regression models 19, [32] [33] [34] [35] .
We estimated MSM parameters by pooled multinomial logistic regression using programming that has previously been published 36 . We computed inverse-probability-of-treatment weights as the patients' probability of having the acute modality that they actually had on day t, as a function of predictive baseline and time-varying covariates (measured at baseline, t and t -24 hours), carrying forward observations in the first day. Stable versions of these weights were computed to avoid bias/imprecision as a result of over-inflated weights from individuals with estimated probabilities very close to 0. We specified MSMs in a manner to meet the assumption of experimental treatment assignment (or positivity). We assessed for model misspecification (leading to incorrect inverseprobability-of-treatment weights) from the distribution of weights 37, 38 . We used a 24-hour lag for attribution of outcomes to modality in the maineffects model.
We computed inverse-probability-of-treatment weights using all potentially confounding variables to avoid the risk of eliminating any that might be true confounders. For the main-effects MSMs, we considered all potentially confounding variables initially and estimated reduced models after removing those with P <0.2 jointly adjusted for other covariates. Statistical significance was assessed at a level of P <0.05.
We used Stata Intercooled MP/11.2 for all analyses (StataCorp, College Station, TX, USA).
RESULTS
Patient and outcome data
Approval for this study was granted by the National (New Zealand) Health and Disability Ethics Committee under the provisions made for clinical audit. We identified an inception cohort of 151 patients with a total of 655 treatment-days. One hundred and forty-six with a total of 633 treatment-days had sufficient data for modelling; five patients and 20 patient-days were omitted because of missing data or because of a second ICU admission in the same patient (n=1). No patient was lost to follow-up. We recorded 49 ICU deaths, 59 hospital deaths and 69 deaths at day 90 post renal replacement therapy inception. We recorded dialysis dependence in 52 of the 97 ICU survivors, 15 of the 87 hospital survivors, and in eight of the 77 survivors at day 90 post renal replacement therapy inception.
Descriptive data
Patient characteristics by modality exposure are provided in Table 1 . In general, those treated with PIRRT and CRRT had higher degrees of illness severity than those treated with iHD.
Renal replacement therapy characteristics are shown in Table 2 . The total number of cumulative days in the cohort between each patient's first and last renal replacement therapy treatments was 845 days. Allowing for 144 days of CRRT, the frequency of intermittent renal replacement therapy with PIRRT or iHD was one treatment per 1.45 days.
Main results
Main results are shown in Table 3 . Unadjusted models show a trend to lower associated hospital mortality risk for iHD relative to both PIRRT and CRRT. After adjustment for baseline and then time varying factors (year of treatment; tertial of lead-time category, baseline SOFA score category, and baseline APACHE IV risk of death category), there was a progressive increase in the mortality risk associated with iHD. In the final fully adjusted model, there were no apparent trends to differences in outcomes by modality.
Other analyses
Supplementary analysis of the secondary endpoint is shown in Table 4 . Unadjusted models show a similar associated 90-day mortality risk for all modalities. However, adjustment for baseline and then time varying factors (as above) resulted in a marked increase in the mortality risk associated with iHD, without any marked change in those associated with PIRRT and CRRT. In the final fully adjusted model, there was a trend to higher 90-day mortality in those receiving iHD relative to both PIRRT and CRRT.
DISCUSSION
In this study, there were no observed differences in hospital mortality between those treated with the different modalities of renal replacement therapy, including PIRRT. This conclusion is consistent with randomised controlled trials comparing iHD and CRRT, and might be considered predictable given the results from these other studies 6, 8, 39 . However, there are specific clinical concerns with PIRRT that need to be allayed by studies such as ours. There are concerns that PIRRT may not provide optimal outcomes for very haemodynamically unstable or shocked patients for whom it is frequently used. Moreover, exposure of critically ill patients for long periods to on-line dialysate (rather than sterile batched dialysate) might carry a risk of exposure to microbial contaminants thereby exacerbating inflammatory milieu. Finally, there are concerns that the relatively greater changes in solutes during PIRRT compared to other modalities might lead to threatening electrolyte abnormalities such as hypokalaemia and hypophosphataemia. Our findings suggest that these issues are not likely to be factors in the routine clinical use of PIRRT by experienced practitioners.
In comparing our findings to the literature, there are only a relatively small number of studies describing mortality risk with PIRRT. Several single-centre observational studies with PIRRT have reported hospital mortality to be at least comparable to that predicted by the APACHE II illness severity scoring system 11, 13, 15, 17, 23, 40, 41 . Several single-centre clinical trials have compared hospital mortality between PIRRT and continuous therapies, and reported similar hospital mortality between those treated with PIRRT and those treated with CRRT (Table 5) [42] [43] [44] . Multi-centre studies are rarer. One observational study used a time series approach in three centres from three different countries, and showed no change in hospital mortality over time with a change from CRRT to PIRRT as the predominant therapy for sicker patients 9 . Potentially the most definitive data was to come from the Stuivenberg Hospital Acute Renal Failure investigators, who provided interim analyses of a large, multi-centre, prospective, randomised clinical trial of 996 patients reporting a hospital mortality of 68% for those treated with PIRRT and 64% for those treated with CRRT 45, 46 . Unfortunately, the most recent publication from the Stuivenberg Hospital Acute Renal Failure investigators described the premature termination of their study, and it is likely that the results of this study will not be seen in final form 47 .
As with most other studies, the group of patients who received CRRT in our study had the highest illness severity as shown by their SOFA scores and APACHE IV score and predicted risk of death. However, our entire patient population had a generally high degree of illness severity, including those who received PIRRT who had severe haemodynamic instability as indicated by their SOFA scores. Our experience reflects findings of a previous research including two small randomised clinical trials: in the hands of experienced practitioners, the effects of CRRT and PIRRT on blood pressure and other haemodynamic parameters are clinically indistinguishable 42, 43, [48] [49] [50] [51] [52] .
In our study, there is a difference between the association between iHD and mortality risk at hospital discharge versus that at 90 days post renal replacement therapy inception. The endpoints of mortality at 90 days post randomisation 53, 54 or at 60 days post randomisation 55, 56 have been used in recent large clinical trials involving renal replacement therapy. The former is recommended by the United Kingdom Medical Research Council International Working Party for Clinical Trials in Patients with Sepsis and Septic Shock 57 , although there is evidence that mortality for patients with AKI may reach a plateau at between 60 and 90 days 58 . In cohort studies that use 'as treated' framework such as ours, the choice of hospital mortality as the primary end-point is important. In our study, the lower associated mortality risk for iHD at hospital discharge versus that at 90 days post renal replacement therapy inception reflects the prognosis of patients who are alive but on iHD at hospital discharge. These patients have delayed or non-recovery of AKI, and are thus at high mortality risk after hospital discharge. It could be argued that modality might affect recovery of renal function to some degree, and by acting through this mechanism, also affect late mortality. However, randomised clinical trials in this area have not shown a difference in renal recovery from AKI by modality [6] [7] [8] . Our study suggests therefore, that mortality at hospital discharge is the most appropriate end-point for cohort studies that use an 'as treated' framework. The potential for selection bias in our study is evident from the differences in baseline and time-varying illness severity scores between groups. In our study, selection bias is minimised in two ways. First, the routine utilisation of PIRRT is somewhat higher in our ICU than it is elsewhere, diminishing selection bias at a patient level. Second, we have made extensive statistical adjustments for risk factors as discussed. The major strength of our study is that it compares all three modalities of renal replacement therapy. Furthermore, the as-treated framework compares deaths in purely one modality with deaths in purely another modality. The intention-to-treat framework in other comparable studies gives biased results if patients change modalities, since the deaths attributed to the allocated modality are actually a mixture of deaths in all modalities 59, 60 . Our results are likely to be a closer approximation of the true 'causal' effect of modality on mortality, as might be determined from of a clinical trial randomising patients to different modalities.
As with all observational studies, associations do not prove causality. There are a number of limitations of this study. The most important shortcoming is the small number of patients, raising the possibility of type II error (i.e. failure to reject a false null hypothesis). The wide confidence intervals of statistical estimates allow for a large number of possible associations, including at worst a 1.5-fold higher associated mortality with PRRT relative to CRRT. Another limitation of this study is likely residual confounding from limited collection of co-morbidity outside of that already recorded in the APACHE IV score (e.g. no collection of functional status, or left ventricular function) and lack of data about blood pressure/ fluid volume status. Notwithstanding, clinical trials comparing outcomes by modality are notoriously difficult and results are often difficult to generalise. Cohort studies are therefore likely to remain a useful source of evidence to guide clinical practice, especially ones such as ours that use contemporary cohorts and state-of-the-art methods for statistical adjustment.
Our observations should be regarded as exploratory and hypothesis-generating, rather than confirmatory and definitive. Further study is needed in patient populations where there is less equipoise about PIRRT over CRRT, such as those with cardiogenic shock, fulminant hepatic failure 61 and brain injury. Acknowledging the significant limitations of our study and others, PIRRT appears to provide non-inferior clinical outcomes compared to CRRT in the general ICU setting.
